Prm46 - Measuring and Analysing the Maturity of Overall Survival Data for Treatments for Relapsed or Refractory Multiple Myeloma

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2169
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Optimizing the Use of Lenalidomide in Relapsed or Refractory Multiple Myeloma: Consensus Statement

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Prm272 - The Eunethta Transferability Tool: Application to Novel Treatments for Relapsed Refractory Multiple Myeloma in the Irish Healthcare Setting

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Treatments for Newly Diagnosed Multiple Myeloma: Analysis of Survival Data and Cost-Effectiveness Evaluation.

Oncology Reports
MedicineCancer ResearchOncology
1998English

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Cancer
Cancer ResearchOncology
2016English

Thalidomide Versus Dexamethasone for the Treatment of Relapsed and/or Refractory Multiple Myeloma: Results From OPTIMUM, a Randomized Trial

Haematologica
Hematology
2011English

Pcn311 - European Market Access Challenges for Relapsed Refractory Multiple Myeloma Triplet Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy